Rapid Response of a BRCA2/TP53/PTEN -Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report | Zendy

Minggui Pan | Zendy; Kristen N. Ganjoo | Zendy; Amer Karam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rapid Response of a BRCA2/TP53/PTEN -Deleted Metastatic Uterine Leiomyosarcoma to Olaparib: A Case Report

Author(s) -

Minggui Pan,

Kristen N. Ganjoo,

Amer Karam

Publication year - 2021

Publication title -

the permanente journal

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.445

H-Index - 30

eISSN - 1552-5775

pISSN - 1552-5767

DOI - 10.7812/tpp/20.251

Subject(s) - olaparib , medicine , gemcitabine , docetaxel , pten , oncology , doxorubicin , temozolomide , leiomyosarcoma , cancer research , chemotherapy , poly adp ribose polymerase , pi3k/akt/mtor pathway , pathology , polymerase , biology , gene , apoptosis , biochemistry

Patients with metastatic uterine leiomyosarcoma (uLMS) have poor prognosis due to limited treatment options, especially when disease progresses on doxorubicin and gemcitabine-docetaxel regimens. Here we report a patient whose metastatic uLMS contains a BRCA2 deep deletion as well as TP53 and PTEN deep deletion. The patient responded rapidly to olaparib, a poly (ADP-ribose) polymerase inhibitor, after progressing on gemcitabine-docetaxel, doxorubicin, and temozolomide regimens. This case report shall be helpful to the treatment of other patients with metastatic uLMS that harbors a BRCA2 mutation or deletion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research